Passa al contenuto
Merck

Documenti fondamentali

Visualizza tutta la documentazione

Vai a

1499403

USP

Paricalcitol

United States Pharmacopeia (USP) Reference Standard

Sinonimo/i:

(1α, 3β, 7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

Cambia visualizzazione
Taglio della confezioneSKUDisponibilitàPrezzo
10 mg
Per conoscere la disponibilità, visualizza il carrello
CHF 4’470.00

Informazioni su questo articolo

Formula empirica (notazione di Hill):
C27H44O3
Numero CAS:
131918-61-1
Peso molecolare:
416.64
MDL number:
MFCD08067734
UNSPSC Code:
41116107
NACRES:
NA.24

CHF 4’470.00

Per conoscere la disponibilità, visualizza il carrello
​
Richiedi un ordine in blocco
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti

grade

pharmaceutical primary standard

API family

paricalcitol

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−20°C

SMILES string

O[C@H]1C[C@@H](CC(=C\C=C2\[C@H]3[C@@]([C@H](CC3)[C@H](C)\C=C\[C@@H](C(O)(C)C)C)(CCC\2)C)C1)O

InChI

1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1

InChI key

BPKAHTKRCLCHEA-UBFJEZKGSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Paricalcitol USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 1

Questo articolo
149941410863011086141
USP

USP

1499403

Paricalcitol

USP

USP

1499414

Paricalcitol solution

USP

USP

1086301

Calcitriol

USP

USP

1086141

Calcipotriene

manufacturer/tradename

USP

manufacturer/tradename

USP

manufacturer/tradename

USP

manufacturer/tradename

USP

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

format

neat

format

neat

format

neat

format

neat

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

API family

paricalcitol

API family

paricalcitol

API family

calcitriol

API family

calcipotriene

storage temp.

−20°C

storage temp.

−20°C

storage temp.

−20°C

storage temp.

2-8°C

Still not finding the right product?

Explore all of our products under

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 2 Inhalation - Acute Tox. 3 Dermal - Acute Tox. 3 Oral - STOT RE 1 Oral

Classe di stoccaggio

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

flash_point_f

Not applicable

flash_point_c

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Jun Cheng et al.
Clinical journal of the American Society of Nephrology : CJASN, 7(3), 391-400 (2012-01-10)
Observational data indicate that newer vitamin D compounds such as paricalcitol can suppress serum intact parathyroid hormone (iPTH) and reduce proteinuria in patients with CKD. To systematically evaluate the efficacy and safety of paricalcitol for CKD, we conducted a meta-analysis
M Cozzolino et al.
Clinical nephrology, 71(6), 593-601 (2009-05-29)
Modern strategies to prevent secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients give great relevance to vitamin D replacement therapy. However, a sound approach to treatment requires taking into account many factors, including stage of CKD, underlying renal disorder
Stefania Pacini et al.
Nutrients, 5(6), 2076-2092 (2013-06-12)
Cardiovascular diseases are more prevalent in patients with chronic kidney disease than in the general population and they are considered the leading cause of death in patients with end-stage renal disease. The discovery that vitamin D3 plays a considerable role
Visualizza tutti i documenti correlati

Numero articolo commerciale globale

SKUGTIN
1499403-10MG04061833860793

Questions

Reviews

No rating value

Active Filters